Exhibit 99.1 Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results Malvern, Pa., August 12, 2025 – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results. "In the past quarter, our efforts were centered on driving enrollment f ...